<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89837</article-id><article-id pub-id-type="pmcid-ver">PMC89837.1</article-id><article-id pub-id-type="pmcaid">89837</article-id><article-id pub-id-type="pmcaiid">89837</article-id><article-id pub-id-type="pmid">10770744</article-id><article-id pub-id-type="doi">10.1128/aac.44.5.1153-1158.2000</article-id><article-id pub-id-type="publisher-id">0756</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Experimental Therapeutics</subject></subj-group></article-categories><title-group><article-title>Activities of Trovafloxacin and Ampicillin-Sulbactam Alone or  in Combination versus Three Strains of Vancomycin- Intermediate <italic>Staphylococcus aureus</italic> in an In Vitro  Pharmacodynamic Infection Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Aeschlimann</surname><given-names initials="JR">Jeffrey R.</given-names></name><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">1</xref><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">2</xref><xref ref-type="author-notes" rid="FN151">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hershberger</surname><given-names initials="E">Ellie</given-names></name><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">1</xref><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rybak</surname><given-names initials="MJ">Michael J.</given-names></name><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">1</xref><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">2</xref><xref ref-type="aff" rid="N0x9ed2a50.0x98c1b90">3</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib></contrib-group><aff id="N0x9ed2a50.0x98c1b90"> The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center,<sup>1</sup> College of Pharmacy and Allied Health Professions,<sup>2</sup> and  School of Medicine,<sup>3</sup> Wayne State University, Detroit, Michigan 48201</aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: The Anti-Infective Research Laboratory, Department of Pharmacy Services (1B), Detroit Receiving Hospital and University Health Center, 4201 St. Antoine Blvd., Detroit, MI 48201. Phone: (313) 745-4554. Fax: (313) 993-2522. E-mail: <email>mrybak@dmc.org</email>.</p></fn><fn id="FN151"><label>&#8224;</label><p>Present address: School of Pharmacy, The University of Connecticut, Storrs, CT 06269.</p></fn></author-notes><pub-date pub-type="ppub"><month>5</month><year>2000</year></pub-date><volume>44</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">2484</issue-id><fpage>1153</fpage><lpage>1158</lpage><history><date date-type="received"><day>7</day><month>9</month><year>1999</year></date><date date-type="rev-request"><day>1</day><month>12</month><year>1999</year></date><date date-type="accepted"><day>31</day><month>1</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>24</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-29 20:25:10.770"><day>29</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac001153.pdf"/><abstract><p>The recent isolation of clinical strains of methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) with intermediate susceptibility (MICs, 8 &#956;g/ml) to vancomycin (vancomycin-intermediate <italic>S. aureus</italic> [VISA]) emphasizes the importance of developing novel antimicrobial regimens and/or agents for future treatment. We studied the activities of ampicillin-sulbactam and trovafloxacin alone or in combination against three unique strains of VISA in an in vitro infection model. Two VISA strains were trovafloxacin susceptible (MICs, &#8804;2 &#956;g/ml); one VISA strain was trovafloxacin resistant (MIC, 4 &#956;g/ml). Trovafloxacin was administered to simulate a dose of 200 or 400 mg every 24 h. Ampicillin-sulbactam was administered to simulate a dose of 3 g every 6 h. Samples were removed from the infection models over 48 h, and reductions in colony counts were compared between regimens. Trovafloxacin (200 mg) produced rapid killing of a control MRSA strain over the 48-h experiment but produced only slight killing of all three VISA strains. The higher dose of trovafloxacin improved killing but did not produce bactericidal activity at 48 h. Ampicillin-sulbactam produced rapid bactericidal activity against all four strains tested, and colony counts at 8 h were at the limits of detection. However, regrowth occurred by 48 h for each strain. The combination of ampicillin-sulbactam and trovafloxacin provided additive activity against two of the three VISA strains. In conclusion, trovafloxacin or ampicillin-sulbactam alone did not provide adequate activity against the VISA strains for the 48-h evaluation period, but the combination could help improve activity against some strains of VISA.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>